ANDA 207721, held by Zydus Pharms. Solifenacin Succinate.
As of Nov 16, 2026, ANDA 207721 (Solifenacin Succinate), held by Zydus Pharms, was first approved by FDA on Oct 19, 2020, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 19, 2020 | Original application | Approved | None posted |
| Solifenacin Succinate5MG · tablet;oral | Solifenacin Succinate | Discontinued |
| Solifenacin Succinate10MG · tablet;oral | Solifenacin Succinate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters